

## 7th Joint Conference of Taiwan and Japan on Medical Products Regulation

Date: October 1, 2019

Location: 11F, Chang Yung-Fa International Convention Center

\*Simultaneous interpretation (Chinese - Japanese) provided

<b>Joint Session (Room 1101)</b>		
<i>MC: Keng-Che Chou, Project Manager, Administration Office II, CDE</i>		
Time	Topics	Speakers
<b>9:00-9:40</b>	<b>Opening Remarks</b> (40 min) *5min each 1. Mr. Ching-Hung Lin, Deputy Secretary General, Taiwan-Japan Relations Association 2. Mr. Mitsuaki Hoshino, Deputy Representative, Japan-Taiwan Exchange Association, Taipei Office 3. Dr. Shou-Mei Wu, Director-General, Taiwan Food and Drug Administration (TFDA) 4. Dr. Yoshikazu Hayashi, Senior Executive Director, Pharmaceuticals and Medical Devices Agency (PMDA) 5. Mr. Tung-Mao Su, Chairman, Taiwan Pharmaceutical Manufacturer's Association (TPMA) 6. Mr. Tadaharu Goto, Director General, Japan Pharmaceutical Manufacturers Association (JPMA) 7. Mr. Francis Hong, Chairman, Taiwan Medical and Biotech Industry Association (TMBIA) 8. Mr. Kenichi Matsumoto, Chairman, Japan Federation of Medical Devices Associations (JFMDA)	
<b>9:40-10:00</b>	<b>Group Photo</b>	
<b>Keynote Speeches</b>		
<b>10:00-10:25</b>	Regulatory Updates in Taiwan	Dr. Shou-Mei Wu Director-General, TFDA Chairperson, Taiwan CDE
<b>10:25-10:50</b>	Regulatory Updates in Japan	Dr. Yoshikazu Hayashi Senior Executive Director, PMDA
<b>10:50-11:00</b>	Q&A	
<b>11:00-11:20</b>	<b>Break</b>	
<b>Regulation on 21st Century Therapies</b>		
Moderator: Dr. Jo-Feng Chi, Researcher, Division of Medicinal Products, TFDA		
<b>11:20-11:40</b>	The Cutting Edge of In Vitro Diagnostics: Regulation on 21st	Dr. Naoyuki Yabana Director, Office of In Vitro Diagnostics,

	Century Therapies	PMDA
<b>11:40-12:00</b>	Flagship Program of Precision Medicine for Asia Pacific Biomedical Silicon Valley	Dr. Shih-Feng Tsai Distinguished Investigator, Institute of Molecular and Genomic Medicine, National Health Research Institutes
<b>12:00-12:10</b>	Q&A	
<b>12:10-13:30</b>	<b>Lunch</b>	

### 【Parallel session (Pharmaceutical)】

\*Simultaneous translation (Japanese-Chinese) provided

<b>Pharmaceutical (Room 1101)</b>		
<b>ICH E17</b>		
Moderator: Mr. Katsuaki Ura, Deputy Director, Office of International Regulatory Affairs, Ministry of Health, Labour and Welfare (MHLW)		
<b>13:30-13:50</b>	Taiwan CDE's Experience to Review MRCT Results	Dr. I-Chun Lai Director, Center of Consultation , CDE
<b>13:50-14:10</b>	Implementation of ICH E17-PMDA's Perspective	Mr. Shuji Kamada Reviewer, Office of New Drug V, PMDA
<b>14:10-14:20</b>	Q&A	
<b>E-labeling Schemes for Medicinal Products</b>		
Moderator: Ms. Ming-Mei Wu, Deputy Director, Division of Medicinal Product, TFDA		
<b>14:20-14:40</b>	E-labeling - Current Status and Future	Dr. Junko Sato Office Director, Office of International Program, PMDA
<b>14:40-15:00</b>	Overview of Drug Information Progress in Taiwan	Mr. Po-Wen Yang Section Chief, Division of Medicinal Products, TFDA
<b>15:00-15:10</b>	Q&A	
<b>15:10-15:30</b>	<b>Break</b>	
<b>Update on OTC Regulation for Appropriate Patient Access</b>		
Moderator: Mr. Naoyuki Yasuda, Director, Office of International Regulatory Affairs, MHLW		
<b>15:30-15:50</b>	Recent Progress of OTC Regulation in Japan	Dr. Hikoichiro Maegawa Deputy Director, Pharmaceutical Evaluation Division, MHLW
<b>15:50-16:10</b>	Regulatory Updates of OTC Drugs in Taiwan	Ms. Hui-Ping Chang Section Chief, Division of Medicinal Products, TFDA

<b>16:10-16:20</b>	Q&A	
<b>16:20-16:40</b>	<b>Break</b>	
<b>Health Insurance</b>		
<b>Recent trend on Health Insurance System</b>		
Moderator: Mr. Ming-Hsun Liu, Director, Division of Medicinal Products, TFDA		
<b>16:40-16:55</b>	Drug Pricing System in Japan	Ms. Hiromi Matsuda Deputy Director, Economic Affairs Division, Health Policy Bureau, MHLW
<b>16:55-17:10</b>	Drug Reimbursement Model and Challenges under Taiwan's NHI System	Ms. Hsueh-Yung (Mary) Tai Director, Medical Review and Pharmaceutical Benefits Division, National Health Insurance Administration (NHIA)
<b>17:10-17:20</b>	Q&A	
<b>17:20-17:30</b>	<b>Closing Remarks (Pharmaceuticals)</b> - Dr. Shou-Mei Wu, Director-General, TFDA - Mr. Naoyuki Yasuda, Director, Office of International Regulatory Affairs, MHLW	
<b>Reception (17:45-)</b>		

**【 Parallel session (Medical Devices) 】**

<b>Medical Devices (Room 801)</b>	
<b>Regulations on In-Vitro Diagnostic Devices</b>	
Moderator: Dr. Chia-Hung Chien, Senior Technical Specialist, Division of Medical Devices and Cosmetics, TFDA	
<b>13:30-13:50</b>	Dr. Jui-Hsiang Lin Senior Reviewer, Division of Medical Devices and Cosmetics, TFDA
<b>13:50-14:10</b>	Dr. Jiro Takei International Policy & Strategy Committee, Asia Subcommittee, JFMDA
<b>14:10-14:20</b>	Q&A
<b>Priority Review Mechanism (Sakigake Designation) for Medical Device Registration</b>	
Moderator: Dr. Chia-Hung Chien, Senior Technical Specialist, Division of Medical Devices and Cosmetics, TFDA	
<b>14:20-14:40</b>	Dr. Cheng-Wen Lan Senior Reviewer, Division of Medical Devices and Cosmetics, TFDA
<b>14:40-15:00</b>	Dr. Mari Shirovani Division Director, Office of International Programs, PMDA
<b>15:00-15:10</b>	Q&A
<b>15:10-15:20</b>	<b>Closing Remarks</b> <ul style="list-style-type: none"><li>- Dr. Hwei-Fang Cheng, Deputy Director General, TFDA</li><li>- Dr. Mari Shirovani, Division Director, Office of International Programs, PMDA</li></ul>
<b>15:20-15:40</b>	<b>Break</b>
<b>Working Group Closed Meeting (Reg. + Industry)</b>	
<b>15:40-17:30</b>	Product Registration WG QMS WG
<b>Reception (17:45-)</b>	